Skip to main content

Table 1 Mean improvement from baseline at Week 12 for patient-reported clinical outcome measures in the total study population and the High-Need cohort.

From: Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]

 

PSA

Itching VAS

PGPA

Patient Population

n

Frequency Mean

Severity Mean

n

Mean

n

Mean

High-Need Cohort

       

   Placebo

184

2.1

1.9

184

0.4

182

0.4

   Efalizumab

340

5.8*

6.3*

339

2.4*

341

2.8*

Total Population

       

   Placebo

262

2.0

1.9

261

0.6

261

0.4

   Efalizumab

527

5.7*

6.2*

526

2.5*

528

2.8*

  1. *P < .001 versus placebo.
  2. PSA, Psoriasis Symptom Assessment; VAS, Visual Analog Scale; PGPA, Patient's Global Psoriasis Assessment.
Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us